FDA Approvals, News & UpdatesMultiple MyelomaNewsworthy

Darzalex-Based Regimen Approved as First Treatment in Patients with Multiple Myeloma Ineligible for Transplant

August 2019 Vol 5 No 4

In June 2019, the FDA approved Darzalex (daratumumab; from Janssen) in combination with Revlimid (lenalidomide; from Celgene) and dexamethasone as the first treatment in patients with multiple myeloma who cannot undergo a stem-cell ­transplant. Darzalex was previously approved for different uses in patients with multiple myeloma.

This latest approval was based on a clinical trial of patients with newly diagnosed multiple myeloma who were not candidates for chemotherapy and a transplant.

Adding Darzalex to the Revlimid plus dexamethasone regimen prolonged the time without disease progression compared with Revlimid plus dexamethasone alone. At the time of the analysis, the average time to disease progression was not reached in patients who received Darzalex (meaning their cancer continues to respond to therapy), but in patients who did not receive Darzalex, the average time to disease progression was 31.9 months.

Adding Darzalex also led to more patients achieving complete response (no sign of cancer) than patients who received only Revlimid and dexamethasone.

Share this:

Recommended For You
Patient StoriesMultiple Myeloma
Living My Life While Dealing with Multiple Myeloma
By Thomas Goode
Thomas Goode always worked out; when he felt an excruciating pain on his left side one day working out, he knew something was wrong and visited a surgeon. After terrible back pain months later and another x-ray and MRI, he was diagnosed with multiple myeloma.
Letters to the EditorMultiple Myeloma
Thank You CONQUER Magazine for a Great Article
By Sally K. Koski, PhD, RN
Sally K. Koski, PhD, RN, expresses her gratitude to CONQUER magazine for the very informative article, “Multiple Myeloma: Navigating the First 90 Days,” which was featured in the April 2022 issue.
Multiple MyelomaPatient Stories
Targeting a Better Future for Patients with Multiple Myeloma
By Christopher Greklek
Christopher Greklek competed in Ironman races and was shocked when he was diagnosed with multiple myeloma. He describes being in and out of remission repeatedly, citing a program seeking to improve patient options.
Last modified: June 10, 2022

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Race or Ethnicity
Profession or Role
Primary Interest